Knight Therapeutics Inc. (TSX:GUD)

Market Cap	628.40M +13.5%
Revenue (ttm)	450.09M +21.2%
Net Income	-5.37M
EPS	-0.05
Shares Out	98.03M
PE Ratio	n/a
Forward PE	37.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,300
Average Volume	79,257
Open	6.43
Previous Close	6.30
Day's Range	6.30 - 6.44
52-Week Range	5.43 - 6.57
Beta	0.18
RSI	61.39
Earnings Date	Mar 19, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD